Management of pituitary gigantism. The role of bromocriptine and radiotherapy.
True gigantism with overproduction of growth hormone (GH) and prolactin (PRL) was diagnosed in two boys, aged 13 years (case I) and 7 1/2 years (case II). Both had shown increased growth rates since early childhood (from 4 years and 1 1/2 years, respectively), but no skeletal acromegalic features were noted. However, both showed increased sweating and both had advanced pubic hair relative to testis volume. No other pituitary dysfunction was recorded. Case I underwent transsphenoidal surgery with only incomplete and temporary suppression of GH and PRL levels. However, in both patients bromocriptine administration promptly suppressed PRL levels. Following combined irradiation and bromocriptine treatment, GH also gradually normalized over a period of 2 years. Both boys are still on treatment, and both showed an increase in plasma GH concentrations when the dose of bromocriptine was reduced or discontinued, indicating that even 3 1/2-5 years after irradiation therapy (and during continuous treatment with bromocriptine) the disease was controlled but not cured. However, in these two boys bromocriptine has proved effective in controlling the PRL/GH oversecretion.
D001827:Body Height; D001971:Bromocriptine / Q000627:therapeutic use*; D002648:Child; D005877:Gigantism / Q000097:blood / Q000209:etiology / Q000532:radiotherapy / Q000628:therapy*; D013006:Growth Hormone / Q000096:biosynthesis; D006801:Humans; D008297:Male; D010911:Pituitary Neoplasms / Q000150:complications / Q000628:therapy; D011388:Prolactin / Q000096:biosynthesis
D001971:Bromocriptine; D011388:Prolactin; D013006:Growth Hormone